Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics Announces Proposed Public Offering of Common Stock
Mar 8, 2017
PDF 282.0 KB Add to Briefcase
View Summary TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL)
Mar 6, 2017
PDF 329.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting
Mar 3, 2017
PDF 284.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab) Monotherapy in the British Journal of Haematology
Feb 21, 2017
PDF 284.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 2017 BIO CEO & Investor Conference
Feb 9, 2017
PDF 278.0 KB Add to Briefcase
View Summary TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for the Treatment of Diffuse Large B-cell Lymphoma
Jan 24, 2017
PDF 282.4 KB Add to Briefcase
View Summary TG Therapeutics Announces Completion of Enrollment and B-cell Depletion Data from Part 1 of Ongoing Phase 2 Multiple Sclerosis Study
Jan 11, 2017
PDF 282.5 KB Add to Briefcase
View Summary TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
Jan 9, 2017
PDF 281.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference
Jan 9, 2017
PDF 278.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Jan 4, 2017
PDF 283.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 2 Trial of TG-1101 (ublituximab) in Combination with Ibrutinib in the British Journal of Haematology
Dec 16, 2016
PDF 283.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Double & Triple Combination Therapy Data Presentations at the 58th American Society of Hematology Annual Meeting
Dec 6, 2016
PDF 320.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces that the GENUINE Phase 3 Study has Reached Target Enrollment
Dec 6, 2016
PDF 281.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Oral Data Presentation for TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL at the 58th American Society of Hematology Annual Meeting
Dec 5, 2016
PDF 287.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Preclinical Data Presentations for TGR-1202 at the 58th American Society of Hematology Annual Meeting
Dec 5, 2016
PDF 288.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Schedule of Data Presentations at the 58th American Society of Hematology Annual Meeting
Dec 2, 2016
PDF 327.5 KB Add to Briefcase
View Summary TG Therapeutics Announces Positive DSMB Recommendation for Continuation of the UNITY-CLL Phase 3 Trial
Nov 22, 2016
PDF 282.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2016 Financial Results
Nov 7, 2016
PDF 298.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2016 Financial Results and Business Update
Nov 3, 2016
PDF 278.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 58th American Society of Hematology Annual Meeting
Nov 3, 2016
PDF 328.2 KB Add to Briefcase
Showing 61-80 of 228 Page: 1 2 3 4 5 6 7 8 ... 12  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase